Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of clostridium perfringens enterotoxin

Cancer

Volumn 117, Issue 24, 2011, Pages 5519-5528

  Casagrande, Francesca ^a   Cocco, Emiliano ^a   Bellone, Stefania ^a   Richter, Christine E ^a   Bellone, Marta ^a   Todeschini, Paola ^a   Siegel, Eric ^b   Varughese, Joyce ^a   Arin Silasi, Dan ^a   Azodi, Masoud ^a   Rutherford, Thomas J ^a   Pecorelli, Sergio ^c   Schwartz, Peter E ^a   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

cancer stem cells; claudin 3; claudin 4; Clostridium perfringens; ovarian neoplasms

Indexed keywords

CARBOPLATIN; CLAUDIN 3; CLAUDIN 4; CLOSTRIDIUM PERFRINGENS ENTEROTOXIN; CLOSTRIDIUM TOXIN; PACLITAXEL; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CLAUDIN 3 GENE; CLAUDIN 4 GENE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT;

ADULT; AGED; ANIMALS; ANTIGENS, CD44; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CLAUDINS; CLOSTRIDIUM PERFRINGENS; ENTEROTOXINS; FEMALE; FLOW CYTOMETRY; HUMANS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, SCID; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; VERO CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052589953     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26215     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
2. Copeland L,. Epithelial ovarian cancer. In:, DiSaia PJ, Creasman WT, eds. Clinical Gynecologic Oncology. St Louis: Mosby Year Book; 1997: 313-367.
3. Reya T, Morrison SJ, Clarke MF, Weissman IL,. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414: 105-111. (Pubitemid 33041634)
4. Dean M, Fojo T, Bates S,. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5: 275-284. (Pubitemid 40488633)
5. Hermann PC, Huber SL, Heeschen C,. Metastatic cancer stem cells: a new target for anti-cancer therapy? Cell Cycle. 2008; 7: 188-193. (Pubitemid 351366518)
6. Mueller MT, Hermann PC, Heeschen C,. Cancer stem cells as new therapeutic target to prevent tumour progression and metastasis. Front Biosci. 2010; 2: 602-613.
7. Bapat SA, Mali AM, Koppikar CB, Kurrey NK,. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 2005; 65: 3025-3029. (Pubitemid 40524578)
8. Zhang S, Balch C, Chan MW, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008; 68: 4311-4320.
9. Alvero AB, Fu HH, Holmberg J, et al. Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells. 2009; 27: 2405-2413.
10. Alvero AB, Chen R, Fu HH, et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle. 2009; 8: 158-166.
11. Katahira J, Inoue N, Horiguchi Y, Matsuda M, Sugimoto N,. Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin. J Cell Biol. 1977; 136: 1239-1247.
12. Katahira J, Sugiyama H, Inoue N, Horiguchi Y, Matsuda M, Sugimoto N,. Clostridium perfringens enterotoxin utilizes 2 structurally related membrane proteins as functional receptors in vivo. J Biol Chem. 1997; 272: 26652-26658. (Pubitemid 27458889)
13. Santin AD, Cane S, Bellone S, et al. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res. 2005; 65: 4334-4342. (Pubitemid 40775672)
14. Kamsteeg M, Rutherford T, Sapi E, et al. Phenoxodiol-an isoflavone analog-induces apoptosis in chemoresistant ovarian cancer cells. Oncogene. 2003; 22: 2611-2620. (Pubitemid 36605609)
15. Landen CN Jr, Goodman B, Katre AA, et al. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther. 2010; 9: 3186-3199.
16. + ovarian cancer cells. Oncogene. 2009; 28: 209-218.
17. Deng S, Yang X, Lassus H, et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One. 2010; 5: e10277.
18. Curley MD, Therrien VA, Cummings CL, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 2009; 27: 2875-2883.
19. Yin G, Chen R, Alvero AB, et al. TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene. 2010; 29: 3545-3553.
20. McClane BA,. An overview of Clostridium perfringens enterotoxin. Toxicon. 1996; 34: 1335-1343. (Pubitemid 27051458)
21. Long H, Crean CD, Lee WH, Cummings OW, Gabig TG,. Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res. 2001; 61: 7878-7881. (Pubitemid 33049378)
22. Michl P, Buchholz M, Rolke M, et al. Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology. 2001; 121: 678-684. (Pubitemid 32822583)
23. Stewart JJ, White JT, Yan X, et al. Proteins associated with cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics. 2006; 5: 433-443.
24. Alberts DS, Markman M, Armstrong D, Rothenberg ML, Muggia F, Howell SB,. Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come. J Clin Oncol. 2002; 20: 3944-3946.